Loss of UBP1 drives oxaliplatin resistance through a targetable dependency on translation initiation
Moustafa Abohawya, Tim Schmäche, Julia Dietzel, Ina Hollerer, Li Ding, Maciej Paszkowski‐Rogacz, Rico Barsacchi, Therese Seidlitz, Sebastián García Tobar, Frank Buchholz, Daniel E. Stange, Jovan Mirectic
The paper identifies UBP1 loss as a driver of oxaliplatin resistance in gastric cancer by revealing a compensatory reliance on translation initiation, which can be targeted with 4EGI.
bioRxiv · May 20, 2026 · PreprintCancer Biology